Clinical Trial Update: Phase 3 Gene Therapy for Painful Diabetic Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results for Helixmith's VM202 gene therapy in painful diabetic neuropathy have been posted after the study was completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Painful Diabetic Neuropathy

Drugs mentioned

• VM202 (hepatocyte growth factor gene therapy)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful | Phase 3 | Status: COMPLETED | Results posted: 2022-08-22